Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12802MR)

This product GTTS-WQ12802MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12802MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7133MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ15670MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ8692MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ14745MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ13326MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ10620MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ1071MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ8586MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW